Femasys (NASDAQ:FEMY) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Femasys (NASDAQ:FEMY) from a strong sell rating to a sell rating in a research report released on Saturday morning,Wall Street Zen reports.

FEMY has been the subject of several other research reports. Maxim Group reduced their price target on shares of Femasys to $10.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Weiss Ratings cut shares of Femasys from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 17th. Finally, Lake Street Capital lowered their price objective on shares of Femasys to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, August 18th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $50.00.

Femasys Price Performance

FEMY stock opened at $1.65 on Friday. Femasys has a one year low of $1.46 and a one year high of $22.20. The firm has a 50-day moving average of $2.48 and a two-hundred day moving average of $4.70. The firm has a market capitalization of $13.83 million, a PE ratio of -0.47 and a beta of -2.16. The company has a current ratio of 2.14, a quick ratio of 0.55 and a debt-to-equity ratio of 0.89.

Femasys (NASDAQ:FEMY) last released its earnings results on Friday, August 14th. The company reported ($1.33) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.02). Femasys had a negative return on equity of 225.97% and a negative net margin of 534.36%. The firm had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.73 million.

Insider Activity

In other Femasys news, CFO Dov Elefant acquired 15,625 shares of Femasys stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average cost of $3.20 per share, with a total value of $50,000.00. Following the purchase, the chief financial officer owned 15,625 shares in the company, valued at approximately $50,000. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kathy Lee-Sepsick acquired 15,625 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were acquired at an average price of $3.20 per share, with a total value of $50,000.00. Following the completion of the transaction, the chief executive officer directly owned 15,625 shares in the company, valued at approximately $50,000. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders purchased 38,750 shares of company stock valued at $124,000. Company insiders own 7.75% of the company’s stock.

About Femasys

Femasys Inc is a biomedical company focused on developing and commercializing therapies and technologies for women’s health. The company’s products are designed to address reproductive health needs, including contraception and infertility, through minimally invasive procedures intended to be performed in a physician’s office.

Femasys’ product portfolio includes FemaSeed, an FDA-cleared intratubal insemination system designed to deliver sperm directly into the fallopian tube during an infertility treatment procedure.